0001896212 false --12-31 Q2 0001896212 2023-01-01 2023-06-30 0001896212 MURF:UnitsEachConsistingOfOneShareOfClassCommonStockAndOneRedeemableWarrantMember 2023-01-01 2023-06-30 0001896212 MURF:ClassCommonStockParValue0.0001PerShareMember 2023-01-01 2023-06-30 0001896212 MURF:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50Member 2023-01-01 2023-06-30 0001896212 us-gaap:CommonClassAMember 2023-08-11 0001896212 us-gaap:CommonClassBMember 2023-08-11 0001896212 2023-06-30 0001896212 2022-12-31 0001896212 us-gaap:CommonClassAMember 2023-06-30 0001896212 us-gaap:CommonClassAMember 2022-12-31 0001896212 us-gaap:CommonClassBMember 2023-06-30 0001896212 us-gaap:CommonClassBMember 2022-12-31 0001896212 2023-04-01 2023-06-30 0001896212 2022-04-01 2022-06-30 0001896212 2022-01-01 2022-06-30 0001896212 us-gaap:CommonClassAMember 2023-04-01 2023-06-30 0001896212 us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001896212 us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001896212 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001896212 us-gaap:CommonClassBMember 2023-04-01 2023-06-30 0001896212 us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001896212 us-gaap:CommonClassBMember 2023-01-01 2023-06-30 0001896212 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-12-31 0001896212 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001896212 us-gaap:RetainedEarningsMember 2022-12-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-03-31 0001896212 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001896212 us-gaap:RetainedEarningsMember 2023-03-31 0001896212 2023-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2021-12-31 0001896212 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001896212 us-gaap:RetainedEarningsMember 2021-12-31 0001896212 2021-12-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-03-31 0001896212 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001896212 us-gaap:RetainedEarningsMember 2022-03-31 0001896212 2022-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-01-01 2023-03-31 0001896212 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001896212 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001896212 2023-01-01 2023-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-04-01 2023-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-04-01 2023-06-30 0001896212 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001896212 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-01-01 2022-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-01-01 2022-03-31 0001896212 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001896212 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001896212 2022-01-01 2022-03-31 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001896212 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001896212 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2023-06-30 0001896212 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001896212 us-gaap:RetainedEarningsMember 2023-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-06-30 0001896212 us-gaap:CommonStockMember us-gaap:CommonClassBMember 2022-06-30 0001896212 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001896212 us-gaap:RetainedEarningsMember 2022-06-30 0001896212 2022-06-30 0001896212 us-gaap:IPOMember 2022-02-06 2022-02-07 0001896212 us-gaap:PrivatePlacementMember 2022-02-06 2022-02-07 0001896212 us-gaap:PrivatePlacementMember 2022-02-07 0001896212 MURF:ConduitPharmaceuticalsLimitedMember 2023-05-11 2023-05-11 0001896212 MURF:BusinessCombinationAgreementMember MURF:ConduitPharmaceuticalsLimitedMember 2022-11-07 2022-11-08 0001896212 MURF:BusinessCombinationAgreementMember MURF:ConduitPharmaceuticalsLimitedMember 2022-11-08 0001896212 MURF:SubscriptionAgreementsMember MURF:ConduitPharmaceuticalsLimitedMember 2022-11-07 2022-11-08 0001896212 us-gaap:IPOMember 2023-06-30 0001896212 MURF:TransactionAgreementMember 2023-01-01 2023-06-30 0001896212 us-gaap:CommonClassAMember 2023-01-26 2023-01-26 0001896212 us-gaap:CommonClassAMember MURF:PublicStockholderMember 2023-01-26 2023-01-26 0001896212 us-gaap:CommonClassAMember MURF:PublicStockholderMember 2023-01-26 0001896212 2023-01-26 2023-01-26 0001896212 2023-01-26 0001896212 MURF:PublicWarrantsMember 2023-01-01 2023-06-30 0001896212 MURF:PrivatePlacementWarrantsMember 2023-01-01 2023-06-30 0001896212 2022-10-01 2022-12-31 0001896212 us-gaap:IPOMember 2023-01-01 2023-06-30 0001896212 us-gaap:CommonClassAMember MURF:PublicWarrantMember us-gaap:IPOMember 2023-06-30 0001896212 us-gaap:PrivatePlacementMember 2023-01-01 2023-06-30 0001896212 us-gaap:PrivatePlacementMember 2023-06-30 0001896212 us-gaap:CapitalUnitClassAMember us-gaap:PrivatePlacementMember 2023-06-30 0001896212 srt:DirectorMember 2023-01-01 2023-06-30 0001896212 MURF:SponsorMember us-gaap:CommonClassBMember 2021-11-16 2021-11-16 0001896212 MURF:SponsorMember 2022-01-25 2022-01-26 0001896212 2021-11-16 2021-11-16 0001896212 us-gaap:CommonClassAMember 2021-11-16 0001896212 MURF:UnsecuredPromissoryNoteMember 2021-11-04 0001896212 MURF:UnsecuredPromissoryNoteMember 2022-02-10 2022-02-10 0001896212 MURF:PromissoryNoteMember 2023-03-07 0001896212 MURF:PromissoryNoteMember 2023-03-06 2023-03-07 0001896212 MURF:PromissoryNoteMember 2023-04-01 2023-06-30 0001896212 MURF:PromissoryNoteMember 2023-06-30 0001896212 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001896212 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001896212 us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001896212 us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001896212 srt:MaximumMember 2023-01-01 2023-06-30 0001896212 us-gaap:OverAllotmentOptionMember srt:MaximumMember 2023-01-01 2023-06-30 0001896212 MURF:UnderwriterMember 2023-01-01 2023-06-30 0001896212 us-gaap:WarrantMember 2023-06-30 0001896212 MURF:PrivatePlacementWarrantsAndPublicWarrantsMember 2023-06-30 0001896212 MURF:PrivatePlacementWarrantsAndPublicWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-06-30 0001896212 MURF:PrivatePlacementWarrantsAndPublicWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001896212 MURF:PrivatePlacementWarrantsAndPublicWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001896212 MURF:PrivatePlacementWarrantsAndPublicWarrantsMember us-gaap:MeasurementInputDiscountRateMember 2023-06-30 0001896212 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001896212 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001896212 2022-01-01 2022-12-31 0001896212 us-gaap:SubsequentEventMember 2023-07-06 0001896212 us-gaap:SubsequentEventMember 2023-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File No. 001-41245

 

MURPHY CANYON ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   87-3272543

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

4995 Murphy Canyon Road, Suite 300

San Diego, California 92123

(Address of Principal Executive Offices, including zip code)
 
760-471-8536
(Registrant’s telephone number, including area code)
 
N/A
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
         
Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant   MURFU   The Nasdaq Stock Market LLC
Class A Common Stock, par value $0.0001 per share   MURF   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50   MURFW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  ☐ Large accelerated filer ☐ Accelerated filer
  Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐

 

As of August 11, 2023, there were 2,941,728 shares of Class A common stock, $0.0001 par value, and 3,306,250 shares of Class B common stock, $0.0001 par value, of the Company issued and outstanding.

 

 

 

   
 

 

MURPHY CANYON ACQUISITION CORP.

Form 10-Q

Table of Contents

 

    Page
Part I. Financial Information  
     
Item 1. Financial Statements 3
  Condensed Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022 (audited) 3
  Unaudited Condensed Statements of Operations for the three and six months ended June 30, 2023 and 2022 4
  Unaudited Condensed Statements of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2023 and 2022 5
  Unaudited Condensed Statement of Cash Flows for the six months ended June 30, 2023 and 2022 6
  Notes to Unaudited Condensed Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk 27
Item 4. Controls and Procedures 27
     
Part II. Other Information  
     
Item 1. Legal Proceedings 28
Item 1A. Risk Factors 28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30
Item 3. Defaults Upon Senior Securities 30
Item 4. Mine Safety Disclosures 30
Item 5. Other Information 30
Item 6. Exhibits 30
     
Part III. Signatures 31

 

2

 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Condensed Financial Statements

 

MURPHY CANYON ACQUISITION CORP.

CONDENSED BALANCE SHEETS

 

   June 30, 2023   December 31, 2022 
   (unaudited)     
         
ASSETS          
Current assets:          
Cash  $277,761   $345,777 
Prepaid expenses   76,729    300,862 
Total current assets   354,490    646,639 
Investments held in Trust Account   23,339,887    136,871,183 
Total Assets  $23,694,377   $137,517,822 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Current liabilities:          
Accrued expenses  $24,528   $43,113 
Income taxes payable   111,724    374,862 
Accrued excise tax   1,140,683    - 
Note payable – Sponsor   750,000    - 
Total current liabilities   2,026,935    417,975 
Deferred commission payable   4,628,750    4,628,750 
Total Liabilities   6,655,685    5,046,725 
           
Commitments and Contingencies (Note 6)   -    - 
           
Common stock subject to possible redemption at redemption value (2,187,728 shares at $10.56 per share and 13,225,000 shares at $10.34 per share, as of June 30, 2023 and December 31, 2022, respectively)   23,108,897    136,771,183 
           
Stockholders’ Deficit          
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding   -    - 
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 754,000 (excluding 2,187,728 shares and 13,225,000 shares subject to possible redemption) issued and outstanding at June 30, 2023, and December 31, 2022, respectively   75    75 
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 3,306,250 shares issued and outstanding   331    331 
Additional paid-in capital   -    - 
Accumulated deficit   (6,070,611)   (4,300,492)
Total Stockholders’ Deficit   (6,070,205)   (4,300,086)
Total Liabilities and Stockholders’ Deficit  $23,694,377   $137,517,822 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

 

MURPHY CANYON ACQUISITION CORP.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

  

For the Three

Months Ended
June 30, 2023

  

For the Three

Months Ended
June 30, 2022

  

For the Six

Months Ended
June 30, 2023

  

For the Six

Months Ended
June 30, 2022

 
General and administrative expenses  $376,266   $249,420   $853,672   $493,138 
Administration fee – related party   30,000    30,000    60,000    50,000 
Total expenses   406,266    279,420    913,672    543,138 
                     
Other Income                    
Interest income – Investments held in Trust Account   275,290    191,585    939,522    201,767 
Total other income   275,290    191,585    939,522    201,767 
Net (loss) income before income taxes   (130,976)   (87,835)   25,850    (341,371)
Income tax expense   (212,735)   (29,704)   (249,292)   (29,704)
Net loss  $(343,711)  $(117,539)  $(223,442)  $(371,075)
Class A common stock – weighted average shares outstanding, basic and diluted   2,941,728    13,979,000    4,344,254    11,105,539 
Class A common stock – Basic and diluted net loss per share  $(0.06)  $(0.01)  $(0.03)  $(0.03)
Class B common stock – weighted average shares outstanding, basic and diluted   3,306,250    3,306,250    3,306,250    3,306,250 
Class B common stock – Basic and diluted net loss per share  $(0.06)  $(0.01)  $(0.03)  $(0.03)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

 

MURPHY CANYON ACQUISITION CORP.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022 (Unaudited)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
   Class A   Class B   Additional Paid-in   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance, January 1, 2023   754,000   $75    3,306,250   $331   $   $(4,300,492)  $(4,300,086)
Remeasurement of Class A common stock subject to possible redemption   -    -    -    -    -    (158,900)   (158,900)
Accrued excise tax on January 24, 2023 redemptions   -    -    -    -    -    (1,140,683)   (1,140,683)
Net income   -    -    -    -    -    120,269    120,269 
Balance, March 31, 2023   754,000   $75    3,306,250   $331   $   $(5,479,806)  $(5,479,400)
Remeasurement of Class A common stock subject to possible redemption   -    -    -    -    -    (247,094)   (247,094)
Net loss   -    -    -    -    -    (343,711)   (343,711)
                                    
Balance, June 30, 2023   754,000   $75    3,306,250   $331   $   $(6,070,611)  $(6,070,205)

 

   Class A   Class B   Additional Paid-in   Accumulated  

Total

Stockholders’ Equity

 
   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
Balance, January 1, 2022   -   $-    3,306,250   $331   $24,669   $(4,381)  $20,619 
Proceeds allocated to Public Warrants, net of offering costs   -    -    -    -    21,917,543    -    21,917,543 
Sale of private placement units, net of offering costs   754,000    75    -    -    7,520,275    -    7,520,350 
Remeasurement of Class A common stock subject to possible redemption   -    -    -    -    (29,462,487)   (2,818,567)   (32,281,054)
Net loss   -    -    -    -    -    (253,536)   (253,536)
Balance, March 31, 2022   754,000    75    3,306,250    331    -    (3,076,484)   (3,076,078)
                                    
Remeasurement of Class A common stock subject to possible redemption   -    -    -    -    -    (101,766)   (101,766)
                                    
Net loss   -    -    -    -    -    (117,539)   (117,539)
                                    
Balance, June 30, 2022   754,000   $75    3,306,250   $331    -   $(3,295,789)  $(3,295,383)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

5

 

 

MURPHY CANYON ACQUISITION CORP.

CONDENSED STATEMENT OF CASH FLOWS

(Unaudited)

 

  

For the Six

Months Ended

June, 2023

  

For the Six

Months Ended

June, 2022

 
         
Cash flows from operating activities:          
Net loss  $(223,442)  $(371,075)
Adjustments to reconcile net loss to net cash used in operating activities          
Interest earned on investments held in Trust Account   (939,522)   (201,767)
Changes in operating assets and liabilities:          
Deferred offering costs   -    108,962 
Prepaid expenses   224,133    (478,716)
Accrued formation and offering costs   -    (15,449)
Accrued expenses   (18,585)   138,645 
Accrued income taxes payable   (263,138)   - 
Net cash used in operating activities   (1,220,554)   (819,400)
Cash flows from investing activities:          
Extension deposit into the Trust Account   (389,942)   - 
Withdrawals from Trust Account for redemptions   114,068,280    - 
Withdrawals from the Trust Account for taxes   792,480    - 
Cash deposited into Trust Account   -    (134,895,000)
Net cash provided by (used in) investing activities   114,470,818    (134,895,000)
Cash flows from financing activities:          
Proceeds from note payable - Sponsor   750,000    - 
Redemptions of Class A common stock   (114,068,280)   - 
Sale of units in public offering   -    132,250,000 
Sale of private placement units   -    7,540,000 
Payment of offering costs   -    (3,109,411)
Repayment of note payable - Sponsor   -    (177,057)
Net cash (used in) provided by financing activities   (113,318,280)   136,503,532 
Net change in cash   (68,016)   789,132 
Cash at beginning of period   345,777    48,555 
Cash at end of period  $277,761   $837,687 
           
Non-cash financing activities:          
Deferred commission payable  $-   $4,628,750 
Accrued excise tax on January 24, 2023 redemptions  $1,140,683    - 
Remeasurement of Class A common stock subject to possible redemption  $405,994   $101,766 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

6

 

 

MURPHY CANYON ACQUISITION CORP.

Notes to financial statements

 

NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

 

Murphy Canyon Acquisition Corp. (the “Company”) was incorporated in Delaware on October 19, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

 

As of June 30, 2023, the Company had not commenced any operations. All activity for the period from October 19, 2021 (inception), through June 30, 2023, relates to the Company’s formation, the proposed initial public offering (“Initial Public Offering”), which is described below, and searching for an initial Business Combination, as defined below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.

 

The registration statement for the Company’s Initial Public Offering (the “Registration Statement”) was declared effective on February 2, 2022. On February 7, 2022, the Company consummated the Initial Public Offering of 13,225,000 units (“Units”), generating gross proceeds of $132,250,000, which is described in Note 3.

 

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 754,000 units (the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in private placements to Murphy Canyon Acquisition Sponsor LLC (the ‘Sponsor” or “our Sponsor”), with gross proceeds of $7,540,000.

 

Following the closing of the Initial Public Offering on February 7, 2022, an amount of $139,790,000 from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement Units was placed in the Trust Account, as defined below. This resulted in an overfunding of the Trust Account of $4,895,000. As such, subsequent to the initial funding of the Trust Account, $2,000,000 was transferred to the Company’s operating cash account and $2,895,000 was used to pay offering costs. The funds held in the Trust Account may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account, as described below.

 

On November 8, 2022, the Company entered into a definitive Business Combination Agreement (the “BCA”) with Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“Conduit”), and Conduit Merger Sub, Inc., a Cayman Islands exempted company (“Merger Sub”). Merger Sub is a wholly owned subsidiary of the Company. Conduit is a pharmaceutical company led by experienced pharma executives, established to fund the development of successful deprioritized clinical assets licensed from large pharmaceutical companies through its exclusive relationships. The BCA was amended in January 2023 and May 2023.

 

On May 11, 2023, the Company, Conduit, and Merger Sub entered into a second amendment to the BCA to provide for (i) removal of the provision that indicates that no tax opinion would be delivered in connection with the closing, (ii) a closing obligation that that the Company either (a) be exempt from the provisions of Rule 419 promulgated under the Securities Act other than through its net tangible assets or (b) have at least $5,000,001 of net tangible assets either immediately prior to or upon consummation of the Business Combination, and (iii) extension of the outside date for the closing of the Business Combination from May 31, 2023, to February 7, 2024.

 

Upon the consummation of the transactions contemplated by the BCA, Merger Sub will merge with and into Conduit, with Conduit surviving as a wholly owned subsidiary of the Company (the “Business Combination”). The Company is expected to be renamed Conduit Pharmaceuticals Inc. at the closing of the Business Combination.

 

Pursuant to the BCA, at the closing, the Company shall issue and deliver to the shareholders of Conduit an aggregate number of shares of the Company’s common stock with an aggregate value equal to $650,000,000, with each share valued at $10.00 per share. A private placement transaction shall be conducted by the Company contemporaneously with the Business Combination (the “PIPE Financing”), pursuant to which the Company has entered into subscription agreements providing for aggregate investments in the Company’s securities of $27,000,000.

 

7

 

 

There can be no assurance that the Business Combination or PIPE Financing will occur as planned or at all.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.

 

The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with our liquidation, if there is a stockholder vote or tender offer in connection with our initial business combination and in connection with certain amendments to our amended and restated certificate of incorporation. In accordance with U.S. Securities and Exchange Commission (“SEC”) and its guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares will be issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A common stock classified as temporary equity will be the allocated proceeds determined in accordance with ASC 470-20. The Class A common stock is subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, we have the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. We have elected to recognize the changes immediately. The accretion or remeasurement will be treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital). The Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption event takes place.

 

If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the outstanding shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.

 

8

 

 

Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company.

 

The holders of the Founder Shares have agreed (a) to waive their redemption rights with respect to the Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to stockholders’ rights or pre-business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

 

If the Company has not completed a Business Combination by February 7, 2024 (“Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Our Sponsor has committed to provide additional funds if needed to make such a deposit for the extensions. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

 

The holders of the Founders Shares have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the holders of Founder Shares acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

 

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company’s independent registered accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 

9

 

 

Initially, the Company was required to complete an initial business combination transaction by 12 months from the consummation of initial public offering or up to 18 months if the Company extended the period of time to consummate a business combination in accordance with the Company’s Certificate of Incorporation. On January 26, 2023, at a special meeting of the Company’s stockholders (the “Special Meeting”), the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to allow the Company to extend, at the Company’s election, the date by which the Company has to consummate a business combination up to 12 times, each such extension for an additional one month period, from February 7, 2023, to February 7, 2024. The Company’s stockholders also approved a related proposal to amend the trust agreement allowing the Company to deposit into the Trust Account, for each one-month extension, one-third of 1% of the funds remaining in the Trust Account following the redemptions made in connection with the approval of the extension proposal at the Special Meeting. At the Special Meeting the Company’s stockholders also approved a proposal to amend the Company’s certificate of incorporation to expand the methods that the Company may employ to not become subject to the “penny stock” rules of the SEC.

 

In connection with such proposals, the Company’s public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. The Company’s public stockholders holding 11,037,272 shares of Class A common stock (out of a total of 13,979,000 shares of Class A common stock) exercised their right to redeem such shares at a redemption price of approximately $10.33 per share. Approximately $114 million in cash was removed from the Trust Account to pay such stockholders and, accordingly, after giving effect to such redemptions, the balance in the Trust Account was approximately $23.3 million.

 

As a result of the approval of such proposals, the Company agreed to deposit into the Trust Account one-third of 1% of the funds then on deposit in the Trust Account for each month of the extension period, resulting in a monthly contribution of approximately $0.035 per share that was not redeemed in connection with the Special Meeting, or an aggregate of approximately $77,000 per month, and an aggregate of $924,000 if the date the Company has to consummate a business combination is extended 12 times, each assuming no interest is earned on the funds in the Trust Account. During the six months ended June 30, 2023, the Company funded approximately $390,000 in monthly extension payments into the Trust Account. The Company continued the extensions in July and August, funding an additional $156,193 into the Trust Account for the two months.

 

Management’s Plan and Going Concern

 

In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial statements. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. Additionally, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. As a result, these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of the uncertainty.

 

10

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

 

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $277,761 and $345,777 in cash as of June 30, 2023 and December 31, 2022, respectively. The Company did not have any cash equivalents as of June 30, 2023 and December 31, 2022.

 

11

 

 

Investments Held in Trust Account

 

At June 30, 2023 and December 31, 2022, the Company had approximately $23.3 million and $136.9 million, respectively, in investments held in the Trust Account.

 

Offering Costs Associated With a Public Offering

 

The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering.” Offering costs of $7,738,161, consisting of $2,645,000 of underwriting fees, $4,628,750 of deferred underwriting fee (which are held in the Trust Account with Wilmington Trust Company acting as trustee), and $464,411 of Initial Public Offering costs. Of these costs, $1,358,457 and $19,656 were allocated to Public Warrants (as defined in Note 3) and Private Placement Warrants (as defined in Note 4), respectively.

 

Class A Common Stock Subject to Possible Redemption

 

The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity”. Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The shares of the Company’s Class A common stock feature certain redemption rights that are considered by the Company to be outside of the Company’s control and subject to the occurrence of uncertain future events.

 

During the six months ended June 30, 2023, 11,037,272 shares of the Class A common stock were redeemed. See Note 1 – Description of Organization, Business Operations and Going Concern for additional information. Accordingly, as of June 30, 2023, the shares of Class A common stock subject to possible redemption in the amount of $23,108,897 are presented as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet.

 

The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of June 30, 2023:

 

Gross proceeds from IPO  $132,250,000 
Less:     
Proceeds allocated to Public Warrants   (23,276,000)
Class A common stock issuance costs   (6,360,054)
Plus:     
Remeasurement adjustment of carrying value to redemption value   32,281,054 
Class A common stock subject to possible redemption, as of March 31, 2022   134,895,000 
Plus:     
Remeasurement adjustment of carrying value to redemption value   1,876,183 
Class A common stock subject to possible redemption as of December 31, 2022  $136,771,183 
Less:     
Redemptions during the three months ended March 31, 2023 *   (114,068,280)
Plus:     
Remeasurement adjustment of carrying value to redemption value   158,900 
Class A common stock subject to possible redemption as of March 31, 2023   22,861,803 
Plus:     
Remeasurement adjustment of carrying value to redemption value   247,094 
Class A common stock subject to possible redemption as of June 30, 2023   23,108,897 

 

12

 

 

Excise Tax

 

In accordance with the Inflation Reduction Act of 2022, the Company accrues the expected excise tax obligation at the end of each reporting period as a cost of redeeming any shares as of that date. In connection with the vote to amend the Company’s certificate of incorporation, holders of 11,037,272 shares of Class A common stock properly exercised their right to redeem their shares of Class A common stock for the aggregate redemption amount of $114,068,280. As such the Company has recorded a 1% excise tax liability in the amount of $1,140,683 on the condensed balance sheet as of June 30, 2023. The liability does not impact the condensed statements of operations or condensed statement cash flows and is an offset against additional paid in capital, to the extent available, and accumulated deficit. This excise tax liability can be offset by future shares of issuance which will be evaluated and adjusted in the period in which the issuances occur. Should the Company liquidate prior to December 31, 2023, the excise tax liability will not be due.

 

Net Income (Loss) per Common Share

 

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value.

 

The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of June 30, 2023, the Company’s outstanding warrants (13,979,000) have been excluded from diluted net loss as their inclusion would be anti-dilutive. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

 

The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts):

 

   Three Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(161,829)  $(181,882)
Denominator:          
Basic and diluted weighted average shares outstanding   2,941,728    3,306,250 
           
Basic and diluted net loss per common share  $(0.06)  $(0.06)

 

   For the Six Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(126,879)  $(96,563)
Denominator:          
Basic and diluted weighted average shares outstanding   4,344,254    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $$(0.03)

 

13

 

 

   For the Three Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(95,057)  $(22,482)
Denominator:          
Basic and diluted weighted average shares outstanding   13,979,000    3,306,250 
           
Basic and diluted net loss per common share  $(0.01)  $(0.01)

 

   For the Six Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(285,946)  $(85,129)
Denominator:          
Basic and diluted weighted average shares outstanding   11,105,539    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $(0.03)

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 or December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.

 

14

 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and investments held in the Trust Account. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Investments Held in Trust Account

 

The Company’s Investments held in the Trust Account were $23.3 million at June 30, 2023, and $136.9 million at December 31, 2022.

 

The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature.

 

Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
     
  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

 

15

 

 

Warrant Instruments

 

The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations.

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 

NOTE 3 — INITIAL PUBLIC OFFERING

 

Pursuant to the Initial Public Offering, the Company sold 13,225,000 Units at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7).

 

NOTE 4 — PRIVATE PLACEMENTS

 

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale to the Sponsor of 754,000 Private Placement Units at a price of $10.00 per Private Placement Unit ($7,540,000). Each Private Placement Unit is comprised of one Class A share and one warrant. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7). Our Sponsor has agreed to transfer, but has not yet transferred, 15,000 placement units to each of our director nominees. The proceeds from the sale of the Private Placement Units will be added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the securities comprising the Private Placement Units will expire worthless. The Private Placement Units (including the Class A common stock issuable upon exercise of the warrants included in the Private Placement Units) will not be transferable, assignable or saleable until 30 days after the completion of an Initial Business Combination, subject to certain exceptions.

 

NOTE 5 — RELATED PARTY TRANSACTIONS

 

Founder Shares

 

On November 16, 2021, the Sponsor received 4,312,500 shares of the Company’s Class B common stock (the “Founder Shares”) for $25,000. On January 26, 2022, the Sponsor surrendered and forfeited 1,006,250 Founder Shares for no consideration, following which the Sponsor holds 3,306,250 Founder Shares.

 

The holders of the Founder Shares have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. However, our sponsor has agreed to transfer, but has not yet transferred, 15,000 placement units to each of our director nominees.

 

16

 

 

Promissory Note — Related Party

 

On November 4, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $300,000. The Promissory Note is non-interest bearing and payable on the earlier of (i) the consummation of the Initial Public Offering or (ii) the decision not to execute the Initial Public Offering. The balance of this Promissory Note in the amount of $177,057 was paid in full on February 10, 2022.

 

On March 7, 2023, the Company entered into a $1.5 million promissory note with the Company’s Sponsor. The promissory note is to fund the Trust Account and the Company’s operating expenses. On March 7, 2023 the Company’s Sponsor advanced $300,000 and an additional $450,000 during the three months ended June 30, 2023. As of June 30, 2023 the outstanding balance on the promissory note totaled $750,000. The Company’s Sponsor will provide additional funds as necessary under the promissory note. This loan is non-interest bearing, unsecured and will be repayable in cash in full upon the earlier of (i) the date on which the Company consummates an initial business combination and (ii) the date that the Company’s winding up is effective.

 

General and Administrative Services

 

Commencing on the date the Units are first listed on the Nasdaq, the Company has agreed to pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of the Initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. During the three and six months ended June 30, 2023, the Company incurred $30,000 and $60,000, respectively, of such expenses. During the three and six months ended June 30, 2022, the Company incurred $30,000 and $50,000, respectively, of such expenses.

 

Related Party Loans

 

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of the notes may be converted upon completion of a Business Combination into units at a price of $10.00 per unit. Such units would be identical to the Private Placement Units. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of June 30, 2023 and December 31, 2022, there was no balance related to a Working Capital Loan with our Sponson that would be convertible into units.

 

NOTE 6 — COMMITMENTS AND CONTINGENCIES

 

Registration Rights

 

The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

17

 

 

Underwriting Agreement

 

The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 1,725,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. The option was fully exercised on February 7, 2022.

 

The underwriters were paid a cash underwriting discount of $0.20 per Unit, or $2,645,000, payable upon the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,628,750. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

In addition to the underwriting discount, the Company paid the underwriters $50,000 as an advance against out-of-pocket accountable expenses actually incurred by the underwriters. The Company agreed to pay or reimburse the underwriters for travel, lodging and other “road show” expenses, expenses of the underwriters’ legal counsel and certain diligence and other fees, which such fees and expenses are capped at an aggregate of $150,000 (less the $50,000 advance previously paid).

 

NOTE 7 — STOCKHOLDERS’ DEFICIT

 

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. As of June 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.

 

Class A Common Stock — The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. As of June 30, 2023 and December 31, 2022, there were 754,000, shares of Class A common stock issued and outstanding (excluding the 2,187,728 shares and 13,225,000 shares subject to possible redemption as of June 30, 2023 and December 31, 2022, respectively). During the six months ended June 30, 2023, a total of 11,037,272, shares of Class A common stock were redeemed for $114,068,280 or approximately $10.33 per share. No additional shares were redeemed during the six months ended June 30, 2023.

 

Class B Common Stock — The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. As of each of June 30, 2023 and December 31, 2022, there were 3,306,250 shares of Class B common stock issued and outstanding.

 

Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering.

 

The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination.

 

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

 

18

 

 

 

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available.

 

The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

 

Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 — Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants:

 

  in whole and not in part;
     
  at a price of $0.01 per Public Warrant;
     
  upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and
     
  if, and only if, the last reported sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganization, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to warrant holders.

 

If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

 

If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless.

 

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering.

 

The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815.

 

19

 

 

The key assumptions used to value the Public Warrants, which was determined to be $23,276,000, were as follows:

 

  Term – 5 years
  Volatility – 22%
  Dividends – 0%
  Discount rate – 1.76%

 

NOTE 8 — FAIR VALUE MEASUREMENTS

 

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

 

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
     
  Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
     
  Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

 

The following table presents information about the Company’s assets and liabilities that are measured at fair value at June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

Description  Level   June 30, 2023 
Assets:          
Investments held in Trust Account   1   $23,339,887 

 

Description  Level   December 31, 2022 
Assets:          
Investments held in Trust Account   1   $136,871,183 

 

NOTE 9 — TAXES

 

The expected tax expense based on the statutory rate is reconciled with actual tax expense as follows:

 

The effective tax rate differs from the statutory tax rate of 21% for the year ended December 31, 2022, due to the valuation allowance recorded on the Company’s net operating losses and unrealized income on the Trust Account. During the three and six months ended June 30, 2023, the estimated effect tax rates is approximately 162% and 964%, respectively, due to the change in the valuation allowance and prior year tax true up. The Company files income tax returns in the U.S. federal jurisdiction and is subject to examination by the various taxing authorities. The Company’s tax returns since inception remain open to examination by the taxing authorities. The Company considers California to be a significant state tax jurisdiction.

 

NOTE 10 — SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were issued. Based upon this review, except as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements other than noted below.

 

On July 6, 2023 and August 7, 2023 the Company deposited into the Trust Account $77,800 and $78,393, respectively, to extend the period of time to consummate a business combination each month.

 

20

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

References to the “Company,” “our,” “us” or “we” refer to Murphy Canyon Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited interim condensed financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans, objectives of management for future operations and the proposed BCA with Conduit (as described below), are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s filings with the SEC. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

 

Overview

 

We are a blank check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We intend to effectuate our initial business combination using cash from the proceeds of the initial public offering and the sale of the placement units, the proceeds of the sale of our shares in connection with our initial business combination (including pursuant to backstop agreements we may enter into), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing.

 

The issuance of additional shares in connection with an initial business combination to the owners of the target or other investors:

 

  may significantly dilute the equity interest of existing shareholders;
     
  may subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common stock;
     
  could cause a change in control if a substantial number of shares of our common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;
     
  may have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and
     
  may adversely affect prevailing market prices for our common stock and warrants.

 

21

 

 

Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:

 

  default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;
     
  acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
     
  our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;
     
  our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;
     
  our inability to pay dividends on our common stock;
     
  using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes;
     
   limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
     
  increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;
     
  limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and
     
  other purposes and other disadvantages compared to our competitors who have less debt.

 

As indicated in the accompanying financial statements, at June 30, 2023 and December 31, 2022, we had $277,761 and $345,777 in cash, respectively. Additionally, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,628,750. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Further, we expect to continue to incur significant costs in the pursuit of our initial business combination plans. We cannot assure you that our plans to raise capital or to complete our initial business combination will be successful.

 

Merger Agreement 

 

On November 8, 2022, we entered into an agreement and plan of merger (together with amendments entered into on January 27, 2023 and May 11, 2023, the “Merger Agreement”) with Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“Conduit”) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and our wholly owned subsidiary. If the Merger Agreement is approved by our stockholders and the transactions under the Merger Agreement are consummated, Merger Sub will merge with and into Conduit, with Conduit surviving the merger as our wholly owned subsidiary (the “Merger”). Upon the closing of the Merger, it is anticipated that we will change our name to “Conduit Pharmaceuticals Inc.” Our board of directors has (i) approved and declared advisable the Merger Agreement, the related ancillary agreements thereto and the transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement and related transactions by our stockholders.

 

Pursuant to the Merger Agreement, the outstanding ordinary shares (including the shares issued upon conversion of all outstanding convertible debt, which conversion shall have occurred prior to the consummation of the Merger Agreement) of Conduit will be converted into an aggregate of 65,000,000 shares of our newly issued common stock, with each such outstanding Conduit ordinary share (including the ordinary shares issued upon conversion of all outstanding convertible debt, which conversion shall have occurred prior to the consummation of the Merger Agreement) converted into newly issued shares of our common stock on a pro rata basis.

 

22

 

 

In connection with the transactions contemplated by the Merger Agreement, we entered into a subscription agreement (the “Subscription Agreement”) with an investor. Pursuant to the Subscription Agreement, the investor has agreed to purchase $27 million (the “Private Placement”) units of our securities, with each unit consisting of (i) one share of common stock and (ii) one warrant to purchase one share of common stock, for a purchase price of $10.00 per unit. The Subscription Agreement contains registration rights, pursuant to which within 15 business days after the closing, we will use reasonable best efforts to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement registering the resale of the shares of common stock included in the units and issued and issuable upon exercise of the warrants. The closing of the Private Placement is conditioned on, among other things, the closing of the Conduit Business Combination.

 

January 2023 Extension

 

Initially, we were required to complete our initial business combination transaction by 12 months from the consummation of our initial public offering or up to 18 months if we extended the period of time to consummate a business combination in accordance with our Certificate of Incorporation. On January 26, 2023, at a special meeting of our stockholders, our stockholders approved a proposal to amend our certificate of incorporation to allow us to extend, at our election, the date by which we have to consummate a business combination up to 12 times, each such extension for an additional one month period, from February 7, 2023, to February 7, 2024. Our stockholders also approved a related proposal to amend the trust agreement allowing us to deposit into the Trust Account, for each one-month extension, one-third of 1% of the funds remaining in the Trust Account following the redemptions made in connection with the approval of the extension proposal at the special meeting. At the special meeting our stockholders also approved a proposal to amend our certificate of incorporation to expand the methods that we may employ to not become subject to the “penny stock” rules of the SEC.

 

In connection with such proposals, our public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. Our public stockholders holding 11,037,272 shares of Class A common stock (out of a total of 13,979,000 shares of Class A common stock) exercised their right to redeem such shares at a redemption price of approximately $10.33 per share. Approximately $114 million in cash was removed from the Trust Account to pay such stockholders and, accordingly, after giving effect to such redemptions, the balance in the Trust Account was approximately $24 million.

 

As a result of the approval of such proposals, we agreed to deposit into the trust account one-third of 1% of the funds then on deposit in the trust account for each month of the extension period, resulting in a monthly contribution of approximately $0.035 per share that was not redeemed in connection with the special meeting, or an aggregate of approximately $77,000 per month, and an aggregate of $924,000 (the “Maximum Contribution”) if the date we have to consummate a business combination is extended 12 times, each assuming no interest is earned on the funds in the trust account. During the six months ended June 30, 2023, the Company funded a total of $389,942 in monthly extension payment into the Trust Account.

 

Results of Operations and Known Trends or Future Events

 

Our entire activity since inception up to June 30, 2023, relates to our formation, our initial public offering and, since the closing of the initial public offering, a search for a business combination candidate. We will not be generating any operating revenues until the closing and completion of our initial business combination.

 

For the three months ended June 30, 2023 and 2022, we had net loss of $343,711 and a net loss of $117,539, respectively. For the three months ended June 30, 2023, this consisted primarily of general and administrative expenses of $376,266, related party administration fees of $30,000 and income tax expense of $212,735. This was offset by interest income of $275,290 earned on Trust assets during the three months June 30, 2023. For the three months ended June 30, 2022, this consisted primarily of general and administrative expenses of $249,420, related party administration fees of $30,000 and income tax expense of 29,704, offset by $191,585 of interest income on Trust assets. The increase in general and administrative expense for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 mainly consists of professional fees for legal and accounting and consulting costs associated with the filing of registration statements with the SEC. There were no registration statements filed with the SEC during the three months ended June 30, 2022.

 

23

 

 

For the six months ended June 30, 2023 and 2022, we had net loss of $223,442 and a net loss of $371,075, respectively. For the six months ended June 30, 2023, this consisted primarily of general and administrative expenses of $853,672, related party administration fees of $60,000 and income tax expense of $249,292. This was offset by interest income of $939,522 earned on Trust assets during the six months June 30, 2023. For the six months ended June 30, 2022, this consisted primarily of general and administrative expenses of $493,138 and related party administration fees of $50,000 and income tax expense of $29,704, offset by $201,767 of interest income on Trust assets. The increase in general and administrative expense for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022 mainly consists of costs for D&O insurance expense, which was not put in place until February 2022, and professional fees for legal and accounting costs associated with the special meeting held in January 2023 and the filing of our registration statements with the SEC. The increase in our income tax expense for the six months ended June 2023 as compared to the same period in 2022 is directly attributable to increase interest income earned on the assets held in Trust over the same time period as noted above.

 

In January 2023, our public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account. Our public stockholders holding 11,037,272 shares of Class A common stock (out of a total of 13,979,000 shares of Class A common stock) exercised their right to redeem such shares at a redemption price of approximately $10.33 per share. Approximately $114 million in cash was removed from the Trust Account to pay such stockholders and, accordingly, after giving effect to such redemptions, the balance in the Trust Account was approximately $24 million. As a result of less funds in the Trust Account, we do not expect the same level of interest income for the second half of the year ended 2023 as we experienced during the second half of the year ended December 31, 2022.

 

Liquidity, Capital Resources and Going Concern

 

As indicated in the accompanying financial statements, at June 30, 2023, we had $277,761 in cash.

 

For the six months ended June 30, 2023, the net decrease in cash was $68,016. Cash used in operating activities was $1,220,554 and was mainly the result of a net loss of $223,442, interest income earned on trust assets $939,522, the change in accrued expenses of $18,585, and the change in income tax payable of $263,138 offset by change in prepaid expense of $224,133. Cash provided by investing activities mainly consisted of $114,068,280 from the Trust Account for redemptions, and $792,480 for tax payments to that state of Delaware and the IRS. This was offset by $389,942 of cash deposited into the trust account for monthly extension payments. Cash used in financing activities was $114,068,280 for redemptions of Class A common stock, offset by $750,000 in funds from our Sponsor for operating activities in connection with a note payable.

 

In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial statements. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. As a result, these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of the uncertainty.

 

Related Party Transactions

 

On November 16, 2021, Murphy Canyon Acquisition Sponsor, LLC, our Sponsor, purchased 4,312,500 founder shares for an aggregate purchase price of $25,000, or approximately $0.006 per share. On January 26, 2022, the Sponsor surrendered and forfeited 1,006,250 Founder Shares for no consideration, following which the Sponsor holds 3,306,250 founder shares at approximately $0.008 per share. The founder shares (including the Class A common stock issuable upon exercise thereof) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder.

 

24

 

 

Commencing on the date of our initial public offering, we pay Murphy Canyon Management Group, Inc., an affiliate of our Sponsor, $10,000 per month for office space, utilities and secretarial and administrative support. For the six months ended June 30, 2023 and 2022, total payments to Murphy Canyon Management Group were $60,000 and $50,000 respectively. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees.

 

Our Sponsor, officers and directors, or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our Sponsor, officers or directors or our or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection with activities on our behalf.

 

On November 4, 2021, our Sponsor loaned us $300,000 to be used for a portion of the expenses of the initial public offering. These loans are non-interest bearing, unsecured and were repaid upon the closing of the initial public offering in February 2022.

 

In addition, in order to finance transaction costs in connection with an intended initial business combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete our initial business combination, we would repay such loaned amounts. In the event that our initial business combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units, at a price of $10.00 per unit at the option of the lender, upon consummation of our initial business combination. The units would be identical to the placement units. The terms of such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to such loans. We do not expect to seek loans from parties other than our Sponsor or an affiliate of our Sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our Trust Account.

 

In connection with the initial public offering, our Sponsor purchased 754,000 placement units for an aggregate purchase price of $7,540,000. Each whole warrant is exercisable to purchase one whole share of Class A common stock at $11.50 per share. Our Sponsor has agreed to transfer, but has not yet transferred, an aggregate of 45,000 placement units (15,000 each) to each of our three independent directors. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the founder shares, or placement units, which will expire worthless if we do not consummate a business combination by February 7, 2024. The placement units are identical to the units sold in the initial public offering except that the placement units and their component securities will not be transferable, assignable or saleable until 30 days after the consummation of our initial business combination except to permitted transferees, the purchasers of the placement units waive any and all rights and claims that they may have to any proceeds, and any interest thereon, held in the Trust Account in respect of the common stock underlying such placement units in the event that a business combination is not consummated. The placement units are entitled registration rights. Additionally, the warrants underlying the placement units contain a cashless exercise provision and shall be non-redeemable while held by the initial purchasers thereof or their permitted assignees. There will be no underwriting fees or commissions due with the respect to the private placement.

 

Our Sponsor has agreed to waive its redemption rights with respect to its founder shares (i) in connection with the consummation of a business combination, (ii) in connection with a stockholder vote to amend our amended and restated certificate of incorporation to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or certain amendments to our charter prior thereto or to redeem 100% of our public shares if we do not complete our initial business combination by February 7, 2024 and (iii) if we fail to consummate a business combination within 12 months from the consummation of our initial public offering (or up to February 7, 2024 at the election of the Company subject to satisfaction of certain conditions) or if we liquidate prior to the expiration of such period. However, our initial stockholders will be entitled to redemption rights with respect to any public shares held by them if we fail to consummate a business combination or liquidate by February 7, 2024.

 

25

 

 

Pursuant to a registration rights agreement we entered into with our initial stockholders, we may be required to register certain securities for sale under the Securities Act. These holders, and holders of units issued upon conversion of working capital loans, if any, are entitled under the registration rights agreement to make up to three demands that we register certain of our securities held by them for sale under the Securities Act and to have the securities covered thereby registered for resale pursuant to Rule 415 under the Securities Act. In addition, these holders have the right to include their securities in other registration statements filed by us. We will bear the costs and expenses of filing any such registration statements.

 

On March 7, 2023, the Company entered into a $1.5 million promissory note with the Company’s Sponsor. The promissory note is to fund the Trust Account and the Company’s operating expenses. On March 7, 2023 the Company’s Sponsor advanced $300,000 and an additional $450,000 during the three months ended June 30, 2023. As of June 30, 2023 the promissory note totaled $750,000. The Company’s Sponsor will provide additional funds as necessary under the promissory note. This loan is non-interest bearing, unsecured and will be repayable in cash in full upon the earlier of (i) the date on which the Company consummates an initial business combination and (ii) the date that the Company’s winding up is effective.

 

Off-Balance Sheet Arrangements; Commitments and Contractual Obligations; Quarterly Results

 

As of June 30, 2023, we did not have any off-balance sheet arrangements and did not have any commitments or contractual obligations.

 

JOBS Act

 

On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We will qualify as an “emerging growth company” and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

 

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company”, we choose to rely on such exemptions we may not be required to, among other things, (i) provide an independent registered public accounting firm’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the report of independent registered public accounting firm providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of the initial public offering or until we are no longer an “emerging growth company,” whichever is earlier.

 

26

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Under the supervision and with the participation of our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2023, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that during the period covered by this report, our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2023, covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

27

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors. 

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes from the risk factors previously disclosed in our Annual Report for the year ended December 31, 2022, except as set forth below. Risks associated with the Merger and Conduit are more fully discussed in the Form S-4 that the Company has filed, as may be amended. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

 

Nasdaq may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.

 

Our securities were listed on the Nasdaq Global Market, a national securities exchange, upon consummation of our initial public offering. Although we met the minimum initial listing standards of Nasdaq, which generally only requires that we meet certain requirements relating to shareholders’ equity, market capitalization, aggregate market value of publicly held shares and distribution requirements, we cannot assure you that our securities will continue to be listed on Nasdaq in the future prior to an initial business combination. The Nasdaq Global Market’s requirements for continued listing include a public float of 1,100,000, a market value of public float of $15,000,000, a market value of listed securities of $50,000,000, and 400 shareholders. The inability to comply with Nasdaq’s continued requirements or standards could result in the delisting of our Class A Common Stock, which could have a material adverse effect on our financial condition and could cause the value of our Class A Common Stock to decline.

 

On April 10, 2023, the Company received written notice (the “Notice”) from Nasdaq indicating that the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on the Nasdaq Global Market (the “MVLS Requirement”). In accordance with Nasdaq rules, the Company has 180 calendar days, or until October 9, 2023 (the “Compliance Date”), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company’s listed securities closes at $50,000,000 or more for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has regained compliance with the MVLS Requirement. If the Company does not regain compliance with the MVLS Requirement by the Compliance Date, the Company will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel. There can be no assurance that such appeal would be successful and Nasdaq would grant the Company’s request for continued listing. If the Company does not regain compliance with the MVLS Requirement by the Compliance Date, the Company may also be able to transfer the listing of its Class A Common Stock to the Nasdaq Capital Market, provided that the Company then meets the applicable requirements for continued listing on the Nasdaq Capital Market.

 

Additionally, in connection with our initial business combination, Nasdaq will require us to file a new initial listing application and meet its initial listing requirements as opposed to its more lenient continued listing requirements. We cannot assure you that we will be able to meet those initial listing requirements at that time.

 

If Nasdaq delists our securities from trading on its exchange, we could face significant material adverse consequences, including:

 

  inability to consummate our initial business combination;
     
  a limited availability of market quotations for our securities;
     
  reduced liquidity with respect to our securities;

 

28

 

 

  a determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;
     
  a limited amount of news and analyst coverage for our company; and
     
  a decreased ability to issue additional securities or obtain additional financing in the future.

 

The Company may be subject to the Excise Tax included in the Inflation Reduction Act of 2022 in the event of a liquidation or in connection with redemptions of its Class A common stock.

 

Under the Inflation Reduction Act of 2022 (the “IRA”), adding Section 4501 to the U.S. Internal Revenue Code of 1986, as amended, a domestic corporation whose stock is traded on an established securities market (a “covered corporation” under the IRA) is subject to an excise tax of 1% on repurchases (redemptions) of its stock after December 31, 2022 (the “Excise Tax”). Because the Company is a Delaware corporation and its securities trade on the Nasdaq Global Market, it is a “covered corporation” within the meaning of the IRA.

 

The IRA became law on August 16, 2022. On December 27, 2022, the IRS published Notice 2023-2, providing “Initial Guidance” regarding the application of the Excise Tax on repurchases of corporate stock under Section 4501. Under these authorities the Company expects the Excise Tax to be imposed on the fair market value of stock repurchased by us. Under a “netting rule”, the fair market value of stock repurchased by the Company may be reduced by the fair market value of securities issued by it in the same taxable year, with the 1% Excise Tax then imposed on the excess, if any, of the value of redemptions over the value of issuances. Therefore, issuances of stock by the Company in connection with its initial business combination transaction (including any PIPE transaction at the time of our initial business combination) will reduce the amount of the Excise Tax in connection with redemptions occurring in the same taxable year. However, a business combination may not be completed during 2023 and, even if a business combination is completed, the fair market value of the securities redeemed may exceed the fair market value of the securities issued in such a combination or otherwise. (The fair market value of securities that are redeemed is determined by the market price of the stock on the day of redemption, regardless of the actual redemption amount.)

 

Further, while the authorities indicate that as a general rule the Excise Tax does not apply in the event of a complete liquidation of a covered corporation, the availability of this exemption under circumstances that might surround the liquidation of a SPAC is not entirely clear.

 

While excise tax returns are generally filed on a quarterly basis, the IRS expects to issue regulations providing that reports of Excise Tax liability are due with the first quarterly excise tax return filed after the close of the taxable year. Except for franchise taxes and income taxes, the proceeds placed in the trust account and the interest earned thereon shall not be used to pay for possible excise tax or any other fees or taxes that may be levied on the Company pursuant to any current, pending or future rules or laws, including without limitation any excise tax due under the IRA on any redemptions or stock buybacks by the Company (except in the case of proceeds that are delivered to the Company following a business combination).

 

In accordance with the IRA, the Company accrues the expected excise tax obligation at the end of each reporting period as a cost of redeeming any shares as of that date. In connection with the vote to amend the Company’s certificate of incorporation, holders of 11,037,272 shares of Class A common stock properly exercised their right to redeem their shares of Class A common stock for the aggregate redemption amount of $114,068,280. As such the Company has recorded a 1% excise tax liability in the amount of $1,140,683 on the condensed balance sheet as of June 30, 2023. The liability does not impact the condensed statements of operations or condensed statement cash flows and is an offset against additional paid in capital, to the extent available, and accumulated deficit. This excise tax liability can be offset by future shares of issuance which will be evaluated and adjusted in the period in which the issuances occur. Should the Company liquidate prior to December 31, 2023, the excise tax liability will not be due.

 

29

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

EXHIBIT INDEX 

 

Exhibit   Description
31.1   Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2   Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
32.2   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
101.INS   Inline XBRL Instance Document*
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.SCH   Inline XBRL Taxonomy Extension Schema Document*
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB   Inline XBRL Taxonomy Extension Labels Linkbase Document*
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

30

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MURPHY CANYON ACQUISITION CORP.
     
August 14, 2023 By: /s/ Jack K. Heilbron
  Name: Jack K. Heilbron
  Title: Chief Executive Officer
    (Principal Executive Officer)
     
August 14, 2023 By: /s/ Adam Sragovicz
  Name: Adam Sragovicz
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

31

 

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

I, Jack K. Heilbron, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. (the Registrant);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

  /s/ Jack K. Heilbron
  Jack K. Heilbron
  Chief Executive Officer (Principal Executive Officer)
   
August 14, 2023  

 

   

 

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

I, Adam Sragovicz, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. (the Registrant);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and we have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent function):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

  /s/ Adam Sragovicz
  Adam Sragovicz
  Chief Financial Officer (Principal Financial Officer)
   
August 14, 2023  

 

   

 

 

 

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

In connection with the accompanying Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. for the period ended June 30, 2023, I, Jack K. Heilbron, Chief Executive Officer of Murphy Canyon Acquisition Corp., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

 

  (1) Such Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. for the period ended June 30, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in such Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. for the period ended June 30, 2023, fairly presents, in all material respects, the financial condition and results of operations of Murphy Canyon Acquisition Corp.

 

  /s/ Jack K. Heilbron
  Jack K. Heilbron
  Chief Executive Officer (Principal Executive Officer)
   
August 14, 2023  

 

A signed original of the certification required by Section 906 has been provided to Murphy Canyon Acquisition Corp. and will be retained by Murphy Canyon Acquisition Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 

   

 

 

 

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

 

In connection with the accompanying Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. for the period ended June 30, 2023, I, Adam Sragovicz, Chief Financial Officer of Murphy Canyon Acquisition Corp., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

 

  (1) Such Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. for the period ended June 30, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in such Quarterly Report on Form 10-Q of Murphy Canyon Acquisition Corp. for the period ended June 30, 2023, fairly presents, in all material respects, the financial condition and results of operations of Murphy Canyon Acquisition Corp.

 

  /s/ Adam Sragovicz
  Adam Sragovicz
  Chief Financial Officer (Principal Financial Officer)
   
August 14, 2023  

 

A signed original of the certification required by Section 906 has been provided to Murphy Canyon Acquisition Corp. and will be retained by Murphy Canyon Acquisition Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 

   

v3.23.2
Cover - shares
6 Months Ended
Jun. 30, 2023
Aug. 11, 2023
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41245  
Entity Registrant Name MURPHY CANYON ACQUISITION CORP.  
Entity Central Index Key 0001896212  
Entity Tax Identification Number 87-3272543  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 4995 Murphy Canyon Road,  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92123  
City Area Code 760  
Local Phone Number 471-8536  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company true  
Units Each Consisting of One Share of Class Common Stock and One Redeemable Warrant [Member]    
Title of 12(b) Security Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant  
Trading Symbol MURFU  
Security Exchange Name NASDAQ  
Class Common Stock Par Value 0.0001 Per Share [Member]    
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share  
Trading Symbol MURF  
Security Exchange Name NASDAQ  
Redeemable Warrants Each Whole Warrant Exercisable for One Share of Class Common Stock at Exercise Price of 11.50 [Member]    
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50  
Trading Symbol MURFW  
Security Exchange Name NASDAQ  
Common Class A [Member]    
Entity Common Stock, Shares Outstanding   2,941,728
Common Class B [Member]    
Entity Common Stock, Shares Outstanding   3,306,250
v3.23.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 277,761 $ 345,777
Prepaid expenses 76,729 300,862
Total current assets 354,490 646,639
Investments held in Trust Account 23,339,887 136,871,183
Total Assets 23,694,377 137,517,822
Current liabilities:    
Accrued expenses 24,528 43,113
Income taxes payable 111,724 374,862
Accrued excise tax 1,140,683
Note payable – Sponsor 750,000
Total current liabilities 2,026,935 417,975
Deferred commission payable 4,628,750 4,628,750
Total Liabilities 6,655,685 5,046,725
Commitments and Contingencies (Note 6)
Common stock subject to possible redemption at redemption value (2,187,728 shares at $10.56 per share and 13,225,000 shares at $10.34 per share, as of June 30, 2023 and December 31, 2022, respectively) 23,108,897 136,771,183
Stockholders’ Deficit    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Additional paid-in capital
Accumulated deficit (6,070,611) (4,300,492)
Total Stockholders’ Deficit (6,070,205) (4,300,086)
Total Liabilities and Stockholders’ Deficit 23,694,377 137,517,822
Common Class A [Member]    
Stockholders’ Deficit    
Common stock, value 75 75
Common Class B [Member]    
Stockholders’ Deficit    
Common stock, value $ 331 $ 331
v3.23.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Shares subject to possible redemption 2,187,728 13,225,000
Temporary equity, redemption price $ 10.56 $ 10.34
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common Class A [Member]    
Shares subject to possible redemption 2,187,728 13,225,000
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 754,000 754,000
Common stock, shares outstanding 754,000 754,000
Common Class B [Member]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 10,000,000 10,000,000
Common stock, shares issued 3,306,250 3,306,250
Common stock, shares outstanding 3,306,250 3,306,250
v3.23.2
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
General and administrative expenses $ 376,266 $ 249,420 $ 853,672 $ 493,138
Administration fee – related party 30,000 30,000 60,000 50,000
Total expenses 406,266 279,420 913,672 543,138
Other Income        
Interest income – Investments held in Trust Account 275,290 191,585 939,522 201,767
Total other income 275,290 191,585 939,522 201,767
Net (loss) income before income taxes (130,976) (87,835) 25,850 (341,371)
Income tax expense (212,735) (29,704) (249,292) (29,704)
Net loss $ (343,711) $ (117,539) $ (223,442) $ (371,075)
Common Class A [Member]        
Other Income        
Common stock - weighted average shares outstanding, basic 2,941,728 13,979,000 4,344,254 11,105,539
Common stock - weighted average shares outstanding, diluted 2,941,728 13,979,000 4,344,254 11,105,539
Common stock - Basic net loss per share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
Common stock - Diluted net loss per share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
Common Class B [Member]        
Other Income        
Common stock - weighted average shares outstanding, basic 3,306,250 3,306,250 3,306,250 3,306,250
Common stock - weighted average shares outstanding, diluted 3,306,250 3,306,250 3,306,250 3,306,250
Common stock - Basic net loss per share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
Common stock - Diluted net loss per share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
v3.23.2
Condensed Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 331 $ 24,669 $ (4,381) $ 20,619
Beginning balance, shares at Dec. 31, 2021 3,306,250      
Remeasurement of Class A common stock subject to possible redemption (29,462,487) (2,818,567) (32,281,054)
Net Income (loss) (253,536) (253,536)
Proceeds allocated to Public Warrants, net of offering costs 21,917,543 21,917,543
Sale of private placement units, net of offering costs $ 75 7,520,275 7,520,350
Sale of private placement units, net of offering costs, shares 754,000        
Ending balance, value at Mar. 31, 2022 $ 75 $ 331 (3,076,484) (3,076,078)
Ending balance, shares at Mar. 31, 2022 754,000 3,306,250      
Beginning balance, value at Dec. 31, 2021 $ 331 24,669 (4,381) 20,619
Beginning balance, shares at Dec. 31, 2021 3,306,250      
Net Income (loss)         (371,075)
Ending balance, value at Jun. 30, 2022 $ 75 $ 331 (3,295,789) (3,295,383)
Ending balance, shares at Jun. 30, 2022 754,000 3,306,250      
Beginning balance, value at Mar. 31, 2022 $ 75 $ 331 (3,076,484) (3,076,078)
Beginning balance, shares at Mar. 31, 2022 754,000 3,306,250      
Remeasurement of Class A common stock subject to possible redemption (101,766) (101,766)
Net Income (loss) (117,539) (117,539)
Ending balance, value at Jun. 30, 2022 $ 75 $ 331 (3,295,789) (3,295,383)
Ending balance, shares at Jun. 30, 2022 754,000 3,306,250      
Beginning balance, value at Dec. 31, 2022 $ 75 $ 331 (4,300,492) (4,300,086)
Beginning balance, shares at Dec. 31, 2022 754,000 3,306,250      
Remeasurement of Class A common stock subject to possible redemption (158,900) (158,900)
Accrued excise tax on January 24, 2023 redemptions (1,140,683) (1,140,683)
Net Income (loss) 120,269 120,269
Ending balance, value at Mar. 31, 2023 $ 75 $ 331 (5,479,806) (5,479,400)
Ending balance, shares at Mar. 31, 2023 754,000 3,306,250      
Beginning balance, value at Dec. 31, 2022 $ 75 $ 331 (4,300,492) (4,300,086)
Beginning balance, shares at Dec. 31, 2022 754,000 3,306,250      
Net Income (loss)         (223,442)
Ending balance, value at Jun. 30, 2023 $ 75 $ 331 (6,070,611) (6,070,205)
Ending balance, shares at Jun. 30, 2023 754,000 3,306,250      
Beginning balance, value at Mar. 31, 2023 $ 75 $ 331 (5,479,806) (5,479,400)
Beginning balance, shares at Mar. 31, 2023 754,000 3,306,250      
Remeasurement of Class A common stock subject to possible redemption (247,094) (247,094)
Net Income (loss) (343,711) (343,711)
Ending balance, value at Jun. 30, 2023 $ 75 $ 331 $ (6,070,611) $ (6,070,205)
Ending balance, shares at Jun. 30, 2023 754,000 3,306,250      
v3.23.2
Condensed Statement of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (223,442) $ (371,075)
Adjustments to reconcile net loss to net cash used in operating activities    
Interest earned on investments held in Trust Account (939,522) (201,767)
Changes in operating assets and liabilities:    
Deferred offering costs 108,962
Prepaid expenses 224,133 (478,716)
Accrued formation and offering costs (15,449)
Accrued expenses (18,585) 138,645
Accrued income taxes payable (263,138)
Net cash used in operating activities (1,220,554) (819,400)
Cash flows from investing activities:    
Extension deposit into the Trust Account (389,942)
Withdrawals from Trust Account for redemptions 114,068,280
Withdrawals from the Trust Account for taxes 792,480
Cash deposited into Trust Account (134,895,000)
Net cash provided by (used in) investing activities 114,470,818 (134,895,000)
Cash flows from financing activities:    
Proceeds from note payable - Sponsor 750,000
Redemptions of Class A common stock (114,068,280)
Sale of units in public offering 132,250,000
Sale of private placement units 7,540,000
Payment of offering costs (3,109,411)
Repayment of note payable - Sponsor (177,057)
Net cash (used in) provided by financing activities (113,318,280) 136,503,532
Net change in cash (68,016) 789,132
Cash at beginning of period 345,777 48,555
Cash at end of period 277,761 837,687
Non-cash financing activities:    
Deferred commission payable 4,628,750
Accrued excise tax on January 24, 2023 redemptions 1,140,683
Remeasurement of Class A common stock subject to possible redemption $ 405,994 $ 101,766
v3.23.2
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

NOTE 1 — DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

 

Murphy Canyon Acquisition Corp. (the “Company”) was incorporated in Delaware on October 19, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

 

As of June 30, 2023, the Company had not commenced any operations. All activity for the period from October 19, 2021 (inception), through June 30, 2023, relates to the Company’s formation, the proposed initial public offering (“Initial Public Offering”), which is described below, and searching for an initial Business Combination, as defined below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end.

 

The registration statement for the Company’s Initial Public Offering (the “Registration Statement”) was declared effective on February 2, 2022. On February 7, 2022, the Company consummated the Initial Public Offering of 13,225,000 units (“Units”), generating gross proceeds of $132,250,000, which is described in Note 3.

 

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 754,000 units (the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in private placements to Murphy Canyon Acquisition Sponsor LLC (the ‘Sponsor” or “our Sponsor”), with gross proceeds of $7,540,000.

 

Following the closing of the Initial Public Offering on February 7, 2022, an amount of $139,790,000 from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement Units was placed in the Trust Account, as defined below. This resulted in an overfunding of the Trust Account of $4,895,000. As such, subsequent to the initial funding of the Trust Account, $2,000,000 was transferred to the Company’s operating cash account and $2,895,000 was used to pay offering costs. The funds held in the Trust Account may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account, as described below.

 

On November 8, 2022, the Company entered into a definitive Business Combination Agreement (the “BCA”) with Conduit Pharmaceuticals Limited, a Cayman Islands exempted company (“Conduit”), and Conduit Merger Sub, Inc., a Cayman Islands exempted company (“Merger Sub”). Merger Sub is a wholly owned subsidiary of the Company. Conduit is a pharmaceutical company led by experienced pharma executives, established to fund the development of successful deprioritized clinical assets licensed from large pharmaceutical companies through its exclusive relationships. The BCA was amended in January 2023 and May 2023.

 

On May 11, 2023, the Company, Conduit, and Merger Sub entered into a second amendment to the BCA to provide for (i) removal of the provision that indicates that no tax opinion would be delivered in connection with the closing, (ii) a closing obligation that that the Company either (a) be exempt from the provisions of Rule 419 promulgated under the Securities Act other than through its net tangible assets or (b) have at least $5,000,001 of net tangible assets either immediately prior to or upon consummation of the Business Combination, and (iii) extension of the outside date for the closing of the Business Combination from May 31, 2023, to February 7, 2024.

 

Upon the consummation of the transactions contemplated by the BCA, Merger Sub will merge with and into Conduit, with Conduit surviving as a wholly owned subsidiary of the Company (the “Business Combination”). The Company is expected to be renamed Conduit Pharmaceuticals Inc. at the closing of the Business Combination.

 

Pursuant to the BCA, at the closing, the Company shall issue and deliver to the shareholders of Conduit an aggregate number of shares of the Company’s common stock with an aggregate value equal to $650,000,000, with each share valued at $10.00 per share. A private placement transaction shall be conducted by the Company contemporaneously with the Business Combination (the “PIPE Financing”), pursuant to which the Company has entered into subscription agreements providing for aggregate investments in the Company’s securities of $27,000,000.

 

 

There can be no assurance that the Business Combination or PIPE Financing will occur as planned or at all.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.

 

The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with our liquidation, if there is a stockholder vote or tender offer in connection with our initial business combination and in connection with certain amendments to our amended and restated certificate of incorporation. In accordance with U.S. Securities and Exchange Commission (“SEC”) and its guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require common stock subject to redemption to be classified outside of permanent equity. Given that the Public Shares will be issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A common stock classified as temporary equity will be the allocated proceeds determined in accordance with ASC 470-20. The Class A common stock is subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, we have the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. We have elected to recognize the changes immediately. The accretion or remeasurement will be treated as a deemed dividend (i.e., a reduction to retained earnings, or in absence of retained earnings, additional paid-in capital). The Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption event takes place.

 

If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the outstanding shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.

 

 

Notwithstanding the foregoing, if the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company.

 

The holders of the Founder Shares have agreed (a) to waive their redemption rights with respect to the Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to stockholders’ rights or pre-business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

 

If the Company has not completed a Business Combination by February 7, 2024 (“Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to pay taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Our Sponsor has committed to provide additional funds if needed to make such a deposit for the extensions. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

 

The holders of the Founders Shares have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the holders of Founder Shares acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

 

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except for the Company’s independent registered accounting firm), prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

 

 

Initially, the Company was required to complete an initial business combination transaction by 12 months from the consummation of initial public offering or up to 18 months if the Company extended the period of time to consummate a business combination in accordance with the Company’s Certificate of Incorporation. On January 26, 2023, at a special meeting of the Company’s stockholders (the “Special Meeting”), the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to allow the Company to extend, at the Company’s election, the date by which the Company has to consummate a business combination up to 12 times, each such extension for an additional one month period, from February 7, 2023, to February 7, 2024. The Company’s stockholders also approved a related proposal to amend the trust agreement allowing the Company to deposit into the Trust Account, for each one-month extension, one-third of 1% of the funds remaining in the Trust Account following the redemptions made in connection with the approval of the extension proposal at the Special Meeting. At the Special Meeting the Company’s stockholders also approved a proposal to amend the Company’s certificate of incorporation to expand the methods that the Company may employ to not become subject to the “penny stock” rules of the SEC.

 

In connection with such proposals, the Company’s public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. The Company’s public stockholders holding 11,037,272 shares of Class A common stock (out of a total of 13,979,000 shares of Class A common stock) exercised their right to redeem such shares at a redemption price of approximately $10.33 per share. Approximately $114 million in cash was removed from the Trust Account to pay such stockholders and, accordingly, after giving effect to such redemptions, the balance in the Trust Account was approximately $23.3 million.

 

As a result of the approval of such proposals, the Company agreed to deposit into the Trust Account one-third of 1% of the funds then on deposit in the Trust Account for each month of the extension period, resulting in a monthly contribution of approximately $0.035 per share that was not redeemed in connection with the Special Meeting, or an aggregate of approximately $77,000 per month, and an aggregate of $924,000 if the date the Company has to consummate a business combination is extended 12 times, each assuming no interest is earned on the funds in the Trust Account. During the six months ended June 30, 2023, the Company funded approximately $390,000 in monthly extension payments into the Trust Account. The Company continued the extensions in July and August, funding an additional $156,193 into the Trust Account for the two months.

 

Management’s Plan and Going Concern

 

In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the Combination Period is less than one year from the date of the issuance of the financial statements. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. Additionally, the Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. As a result, these factors raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of the uncertainty.

 

 

v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

 

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $277,761 and $345,777 in cash as of June 30, 2023 and December 31, 2022, respectively. The Company did not have any cash equivalents as of June 30, 2023 and December 31, 2022.

 

 

Investments Held in Trust Account

 

At June 30, 2023 and December 31, 2022, the Company had approximately $23.3 million and $136.9 million, respectively, in investments held in the Trust Account.

 

Offering Costs Associated With a Public Offering

 

The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering.” Offering costs of $7,738,161, consisting of $2,645,000 of underwriting fees, $4,628,750 of deferred underwriting fee (which are held in the Trust Account with Wilmington Trust Company acting as trustee), and $464,411 of Initial Public Offering costs. Of these costs, $1,358,457 and $19,656 were allocated to Public Warrants (as defined in Note 3) and Private Placement Warrants (as defined in Note 4), respectively.

 

Class A Common Stock Subject to Possible Redemption

 

The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity”. Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The shares of the Company’s Class A common stock feature certain redemption rights that are considered by the Company to be outside of the Company’s control and subject to the occurrence of uncertain future events.

 

During the six months ended June 30, 2023, 11,037,272 shares of the Class A common stock were redeemed. See Note 1 – Description of Organization, Business Operations and Going Concern for additional information. Accordingly, as of June 30, 2023, the shares of Class A common stock subject to possible redemption in the amount of $23,108,897 are presented as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet.

 

The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of June 30, 2023:

 

Gross proceeds from IPO  $132,250,000 
Less:     
Proceeds allocated to Public Warrants   (23,276,000)
Class A common stock issuance costs   (6,360,054)
Plus:     
Remeasurement adjustment of carrying value to redemption value   32,281,054 
Class A common stock subject to possible redemption, as of March 31, 2022   134,895,000 
Plus:     
Remeasurement adjustment of carrying value to redemption value   1,876,183 
Class A common stock subject to possible redemption as of December 31, 2022  $136,771,183 
Less:     
Redemptions during the three months ended March 31, 2023 *   (114,068,280)
Plus:     
Remeasurement adjustment of carrying value to redemption value   158,900 
Class A common stock subject to possible redemption as of March 31, 2023   22,861,803 
Plus:     
Remeasurement adjustment of carrying value to redemption value   247,094 
Class A common stock subject to possible redemption as of June 30, 2023   23,108,897 

 

 

Excise Tax

 

In accordance with the Inflation Reduction Act of 2022, the Company accrues the expected excise tax obligation at the end of each reporting period as a cost of redeeming any shares as of that date. In connection with the vote to amend the Company’s certificate of incorporation, holders of 11,037,272 shares of Class A common stock properly exercised their right to redeem their shares of Class A common stock for the aggregate redemption amount of $114,068,280. As such the Company has recorded a 1% excise tax liability in the amount of $1,140,683 on the condensed balance sheet as of June 30, 2023. The liability does not impact the condensed statements of operations or condensed statement cash flows and is an offset against additional paid in capital, to the extent available, and accumulated deficit. This excise tax liability can be offset by future shares of issuance which will be evaluated and adjusted in the period in which the issuances occur. Should the Company liquidate prior to December 31, 2023, the excise tax liability will not be due.

 

Net Income (Loss) per Common Share

 

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value.

 

The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of June 30, 2023, the Company’s outstanding warrants (13,979,000) have been excluded from diluted net loss as their inclusion would be anti-dilutive. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

 

The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts):

 

   Three Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(161,829)  $(181,882)
Denominator:          
Basic and diluted weighted average shares outstanding   2,941,728    3,306,250 
           
Basic and diluted net loss per common share  $(0.06)  $(0.06)

 

   For the Six Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(126,879)  $(96,563)
Denominator:          
Basic and diluted weighted average shares outstanding   4,344,254    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $$(0.03)

 

 

   For the Three Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(95,057)  $(22,482)
Denominator:          
Basic and diluted weighted average shares outstanding   13,979,000    3,306,250 
           
Basic and diluted net loss per common share  $(0.01)  $(0.01)

 

   For the Six Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(285,946)  $(85,129)
Denominator:          
Basic and diluted weighted average shares outstanding   11,105,539    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $(0.03)

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 or December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.

 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and investments held in the Trust Account. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Investments Held in Trust Account

 

The Company’s Investments held in the Trust Account were $23.3 million at June 30, 2023, and $136.9 million at December 31, 2022.

 

The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

 

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature.

 

Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
     
  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

 

 

Warrant Instruments

 

The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations.

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

 

v3.23.2
INITIAL PUBLIC OFFERING
6 Months Ended
Jun. 30, 2023
Initial Public Offering  
INITIAL PUBLIC OFFERING

NOTE 3 — INITIAL PUBLIC OFFERING

 

Pursuant to the Initial Public Offering, the Company sold 13,225,000 Units at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7).

 

v3.23.2
PRIVATE PLACEMENTS
6 Months Ended
Jun. 30, 2023
Private Placements  
PRIVATE PLACEMENTS

NOTE 4 — PRIVATE PLACEMENTS

 

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale to the Sponsor of 754,000 Private Placement Units at a price of $10.00 per Private Placement Unit ($7,540,000). Each Private Placement Unit is comprised of one Class A share and one warrant. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment (see Note 7). Our Sponsor has agreed to transfer, but has not yet transferred, 15,000 placement units to each of our director nominees. The proceeds from the sale of the Private Placement Units will be added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the securities comprising the Private Placement Units will expire worthless. The Private Placement Units (including the Class A common stock issuable upon exercise of the warrants included in the Private Placement Units) will not be transferable, assignable or saleable until 30 days after the completion of an Initial Business Combination, subject to certain exceptions.

 

v3.23.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 5 — RELATED PARTY TRANSACTIONS

 

Founder Shares

 

On November 16, 2021, the Sponsor received 4,312,500 shares of the Company’s Class B common stock (the “Founder Shares”) for $25,000. On January 26, 2022, the Sponsor surrendered and forfeited 1,006,250 Founder Shares for no consideration, following which the Sponsor holds 3,306,250 Founder Shares.

 

The holders of the Founder Shares have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. However, our sponsor has agreed to transfer, but has not yet transferred, 15,000 placement units to each of our director nominees.

 

 

Promissory Note — Related Party

 

On November 4, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $300,000. The Promissory Note is non-interest bearing and payable on the earlier of (i) the consummation of the Initial Public Offering or (ii) the decision not to execute the Initial Public Offering. The balance of this Promissory Note in the amount of $177,057 was paid in full on February 10, 2022.

 

On March 7, 2023, the Company entered into a $1.5 million promissory note with the Company’s Sponsor. The promissory note is to fund the Trust Account and the Company’s operating expenses. On March 7, 2023 the Company’s Sponsor advanced $300,000 and an additional $450,000 during the three months ended June 30, 2023. As of June 30, 2023 the outstanding balance on the promissory note totaled $750,000. The Company’s Sponsor will provide additional funds as necessary under the promissory note. This loan is non-interest bearing, unsecured and will be repayable in cash in full upon the earlier of (i) the date on which the Company consummates an initial business combination and (ii) the date that the Company’s winding up is effective.

 

General and Administrative Services

 

Commencing on the date the Units are first listed on the Nasdaq, the Company has agreed to pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of the Initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. During the three and six months ended June 30, 2023, the Company incurred $30,000 and $60,000, respectively, of such expenses. During the three and six months ended June 30, 2022, the Company incurred $30,000 and $50,000, respectively, of such expenses.

 

Related Party Loans

 

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of the notes may be converted upon completion of a Business Combination into units at a price of $10.00 per unit. Such units would be identical to the Private Placement Units. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of June 30, 2023 and December 31, 2022, there was no balance related to a Working Capital Loan with our Sponson that would be convertible into units.

 

v3.23.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 — COMMITMENTS AND CONTINGENCIES

 

Registration Rights

 

The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

 

Underwriting Agreement

 

The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 1,725,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. The option was fully exercised on February 7, 2022.

 

The underwriters were paid a cash underwriting discount of $0.20 per Unit, or $2,645,000, payable upon the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,628,750. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

In addition to the underwriting discount, the Company paid the underwriters $50,000 as an advance against out-of-pocket accountable expenses actually incurred by the underwriters. The Company agreed to pay or reimburse the underwriters for travel, lodging and other “road show” expenses, expenses of the underwriters’ legal counsel and certain diligence and other fees, which such fees and expenses are capped at an aggregate of $150,000 (less the $50,000 advance previously paid).

 

v3.23.2
STOCKHOLDERS’ DEFICIT
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
STOCKHOLDERS’ DEFICIT

NOTE 7 — STOCKHOLDERS’ DEFICIT

 

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. As of June 30, 2023 and December 31, 2022, there were no shares of preferred stock issued or outstanding.

 

Class A Common Stock — The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. As of June 30, 2023 and December 31, 2022, there were 754,000, shares of Class A common stock issued and outstanding (excluding the 2,187,728 shares and 13,225,000 shares subject to possible redemption as of June 30, 2023 and December 31, 2022, respectively). During the six months ended June 30, 2023, a total of 11,037,272, shares of Class A common stock were redeemed for $114,068,280 or approximately $10.33 per share. No additional shares were redeemed during the six months ended June 30, 2023.

 

Class B Common Stock — The Company is authorized to issue 10,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. As of each of June 30, 2023 and December 31, 2022, there were 3,306,250 shares of Class B common stock issued and outstanding.

 

Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a stockholders agreement or other arrangements with the stockholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of this offering.

 

The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination.

 

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

 

 

 

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available.

 

The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

 

Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 — Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants:

 

  in whole and not in part;
     
  at a price of $0.01 per Public Warrant;
     
  upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and
     
  if, and only if, the last reported sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganization, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to warrant holders.

 

If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

 

If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless.

 

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering.

 

The Private Placement Warrants and Public Warrants are recorded in stockholders’ equity (deficit) as they qualify for equity treatment under ASC 815.

 

 

The key assumptions used to value the Public Warrants, which was determined to be $23,276,000, were as follows:

 

  Term – 5 years
  Volatility – 22%
  Dividends – 0%
  Discount rate – 1.76%

 

v3.23.2
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS

NOTE 8 — FAIR VALUE MEASUREMENTS

 

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

 

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
     
  Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
     
  Level 3: Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

 

The following table presents information about the Company’s assets and liabilities that are measured at fair value at June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

Description  Level   June 30, 2023 
Assets:          
Investments held in Trust Account   1   $23,339,887 

 

Description  Level   December 31, 2022 
Assets:          
Investments held in Trust Account   1   $136,871,183 

 

v3.23.2
TAXES
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
TAXES

NOTE 9 — TAXES

 

The expected tax expense based on the statutory rate is reconciled with actual tax expense as follows:

 

The effective tax rate differs from the statutory tax rate of 21% for the year ended December 31, 2022, due to the valuation allowance recorded on the Company’s net operating losses and unrealized income on the Trust Account. During the three and six months ended June 30, 2023, the estimated effect tax rates is approximately 162% and 964%, respectively, due to the change in the valuation allowance and prior year tax true up. The Company files income tax returns in the U.S. federal jurisdiction and is subject to examination by the various taxing authorities. The Company’s tax returns since inception remain open to examination by the taxing authorities. The Company considers California to be a significant state tax jurisdiction.

 

v3.23.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 10 — SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date the financial statements were issued. Based upon this review, except as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements other than noted below.

 

On July 6, 2023 and August 7, 2023 the Company deposited into the Trust Account $77,800 and $78,393, respectively, to extend the period of time to consummate a business combination each month.

v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”).

 

Emerging Growth Company

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $277,761 and $345,777 in cash as of June 30, 2023 and December 31, 2022, respectively. The Company did not have any cash equivalents as of June 30, 2023 and December 31, 2022.

 

 

Investments Held in Trust Account

Investments Held in Trust Account

 

At June 30, 2023 and December 31, 2022, the Company had approximately $23.3 million and $136.9 million, respectively, in investments held in the Trust Account.

 

Offering Costs Associated With a Public Offering

Offering Costs Associated With a Public Offering

 

The Company complies with the requirements of FASB ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A — “Expenses of Offering.” Offering costs of $7,738,161, consisting of $2,645,000 of underwriting fees, $4,628,750 of deferred underwriting fee (which are held in the Trust Account with Wilmington Trust Company acting as trustee), and $464,411 of Initial Public Offering costs. Of these costs, $1,358,457 and $19,656 were allocated to Public Warrants (as defined in Note 3) and Private Placement Warrants (as defined in Note 4), respectively.

 

Class A Common Stock Subject to Possible Redemption

Class A Common Stock Subject to Possible Redemption

 

The Company accounts for its shares of Class A common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity”. Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The shares of the Company’s Class A common stock feature certain redemption rights that are considered by the Company to be outside of the Company’s control and subject to the occurrence of uncertain future events.

 

During the six months ended June 30, 2023, 11,037,272 shares of the Class A common stock were redeemed. See Note 1 – Description of Organization, Business Operations and Going Concern for additional information. Accordingly, as of June 30, 2023, the shares of Class A common stock subject to possible redemption in the amount of $23,108,897 are presented as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet.

 

The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of June 30, 2023:

 

Gross proceeds from IPO  $132,250,000 
Less:     
Proceeds allocated to Public Warrants   (23,276,000)
Class A common stock issuance costs   (6,360,054)
Plus:     
Remeasurement adjustment of carrying value to redemption value   32,281,054 
Class A common stock subject to possible redemption, as of March 31, 2022   134,895,000 
Plus:     
Remeasurement adjustment of carrying value to redemption value   1,876,183 
Class A common stock subject to possible redemption as of December 31, 2022  $136,771,183 
Less:     
Redemptions during the three months ended March 31, 2023 *   (114,068,280)
Plus:     
Remeasurement adjustment of carrying value to redemption value   158,900 
Class A common stock subject to possible redemption as of March 31, 2023   22,861,803 
Plus:     
Remeasurement adjustment of carrying value to redemption value   247,094 
Class A common stock subject to possible redemption as of June 30, 2023   23,108,897 

 

 

Excise Tax

Excise Tax

 

In accordance with the Inflation Reduction Act of 2022, the Company accrues the expected excise tax obligation at the end of each reporting period as a cost of redeeming any shares as of that date. In connection with the vote to amend the Company’s certificate of incorporation, holders of 11,037,272 shares of Class A common stock properly exercised their right to redeem their shares of Class A common stock for the aggregate redemption amount of $114,068,280. As such the Company has recorded a 1% excise tax liability in the amount of $1,140,683 on the condensed balance sheet as of June 30, 2023. The liability does not impact the condensed statements of operations or condensed statement cash flows and is an offset against additional paid in capital, to the extent available, and accumulated deficit. This excise tax liability can be offset by future shares of issuance which will be evaluated and adjusted in the period in which the issuances occur. Should the Company liquidate prior to December 31, 2023, the excise tax liability will not be due.

 

Net Income (Loss) per Common Share

Net Income (Loss) per Common Share

 

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share”. Net income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding for the period. Accretion associated with the redeemable shares of Class A common stock is excluded from income (loss) per common share as the redemption value approximates fair value.

 

The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering, and (ii) the private placement since the exercise of the warrants is contingent upon the occurrence of future events. As of June 30, 2023, the Company’s outstanding warrants (13,979,000) have been excluded from diluted net loss as their inclusion would be anti-dilutive. As a result, diluted net income (loss) per common share is the same as basic net income (loss) per common share for the periods presented.

 

The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts):

 

   Three Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(161,829)  $(181,882)
Denominator:          
Basic and diluted weighted average shares outstanding   2,941,728    3,306,250 
           
Basic and diluted net loss per common share  $(0.06)  $(0.06)

 

   For the Six Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(126,879)  $(96,563)
Denominator:          
Basic and diluted weighted average shares outstanding   4,344,254    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $$(0.03)

 

 

   For the Three Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(95,057)  $(22,482)
Denominator:          
Basic and diluted weighted average shares outstanding   13,979,000    3,306,250 
           
Basic and diluted net loss per common share  $(0.01)  $(0.01)

 

   For the Six Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(285,946)  $(85,129)
Denominator:          
Basic and diluted weighted average shares outstanding   11,105,539    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $(0.03)

 

Income Taxes

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 or December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

The Company has identified the United States and California as its only tax jurisdictions. The Company is subject to income taxation by major taxing authorities since inception. All tax periods are open to examination by tax authorities. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The Company actual tax expense differs from the expected tax expense due to the change in the valuation allowance.

 

 

Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist principally of cash and investments held in the Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000, and investments held in the Trust Account. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Investments Held in Trust Account

Investments Held in Trust Account

 

The Company’s Investments held in the Trust Account were $23.3 million at June 30, 2023, and $136.9 million at December 31, 2022.

 

The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements” approximates the carrying amounts represented in the balance sheet, partially due to their short-term nature.

 

Fair value is defined as the price that would be received for sale of an asset or paid to transfer of a liability, in an orderly transaction between market participants at the measurement date. US GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
     
  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
     
  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

Derivative Financial Instruments

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

 

 

Warrant Instruments

Warrant Instruments

 

The Company accounts for warrants in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 warrants that meet the criteria for equity treatment are recorded in stockholders’ equity (deficit). The warrants are subject to re-evaluation of the proper classification and accounting treatment at each reporting period. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statement of operations.

 

Recent Accounting Standards

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION

The following table provides a reconciliation of the shares of Class A common stock subject to possible redemption reflected on the balance sheet as of June 30, 2023:

 

Gross proceeds from IPO  $132,250,000 
Less:     
Proceeds allocated to Public Warrants   (23,276,000)
Class A common stock issuance costs   (6,360,054)
Plus:     
Remeasurement adjustment of carrying value to redemption value   32,281,054 
Class A common stock subject to possible redemption, as of March 31, 2022   134,895,000 
Plus:     
Remeasurement adjustment of carrying value to redemption value   1,876,183 
Class A common stock subject to possible redemption as of December 31, 2022  $136,771,183 
Less:     
Redemptions during the three months ended March 31, 2023 *   (114,068,280)
Plus:     
Remeasurement adjustment of carrying value to redemption value   158,900 
Class A common stock subject to possible redemption as of March 31, 2023   22,861,803 
Plus:     
Remeasurement adjustment of carrying value to redemption value   247,094 
Class A common stock subject to possible redemption as of June 30, 2023   23,108,897 

SCHEDULE OF BASIC AND DILUTED NET LOSS PER COMMON SHARE

The following table reflects the calculation of basic and diluted net loss per common share (in dollars, except per share amounts):

 

   Three Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(161,829)  $(181,882)
Denominator:          
Basic and diluted weighted average shares outstanding   2,941,728    3,306,250 
           
Basic and diluted net loss per common share  $(0.06)  $(0.06)

 

   For the Six Months Ended 
   June 30, 2023 
  

Class A common

stock

  

Class B common

stock

 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(126,879)  $(96,563)
Denominator:          
Basic and diluted weighted average shares outstanding   4,344,254    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $$(0.03)

 

 

   For the Three Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(95,057)  $(22,482)
Denominator:          
Basic and diluted weighted average shares outstanding   13,979,000    3,306,250 
           
Basic and diluted net loss per common share  $(0.01)  $(0.01)

 

   For the Six Months Ended 
   June 30, 2022 
   Class A common
stock
   Class B common
stock
 
Basic and diluted net loss per common share          
Numerator:          
Allocation of net loss  $(285,946)  $(85,129)
Denominator:          
Basic and diluted weighted average shares outstanding   11,105,539    3,306,250 
           
Basic and diluted net loss per common share  $(0.03)  $(0.03)
v3.23.2
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES

The following table presents information about the Company’s assets and liabilities that are measured at fair value at June 30, 2023 and December 31, 2022, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

Description  Level   June 30, 2023 
Assets:          
Investments held in Trust Account   1   $23,339,887 

 

Description  Level   December 31, 2022 
Assets:          
Investments held in Trust Account   1   $136,871,183 
v3.23.2
DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
May 11, 2023
Jan. 26, 2023
Nov. 08, 2022
Feb. 07, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Nov. 16, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Proceeds from isssuance           $ 132,250,000 $ 132,250,000    
Offering costs             $ 4,628,750      
Stock issued value, acquisitions   $ 924,000                
Share issued price per share   $ 0.035                
Business combination description of transaction             The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Initial Public Offering, management has agreed that an amount equal to at least $10.00 per Unit sold in the Initial Public Offering, including proceeds of the Private Placement Warrants, will be held in a trust account (“Trust Account”), located in the United States and invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below      
Retained earnings restrictions             the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company      
Debt instrument redemption price percentage             100.00%      
Interest expense             $ 100,000      
Percentage of deposit in trust account   1.00%                
Redemption price per share             $ 10.56   $ 10.34  
Number of stock redeemed, value   $ 114,000,000     $ 114,068,280          
Investments held in trust account   23,300,000         $ 23,339,887   $ 136,871,183  
Aggregate of deposit   $ 77,000                
Payments to Acquire Investments to be Held in Decommissioning Trust Fund             389,942    
Additional payments             $ 156,193      
Common Class A [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Sale of stock price per share                   $ 12.00
Share issued price per share             $ 10.33      
Percentage of deposit in trust account   1.00%                
Number of stock redeemed, value             $ 114,068,280      
Common Class A [Member] | Public Stockholder [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock issued during period shares on hold   11,037,272                
Stock issued   13,979,000                
Redemption price per share   $ 10.33                
Transaction Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Business combination description of transaction             (i) $10.00 per Public Share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per public Share due to reductions in the value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”)      
Conduit Pharmaceuticals Limited [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Business combination description (i) removal of the provision that indicates that no tax opinion would be delivered in connection with the closing, (ii) a closing obligation that that the Company either (a) be exempt from the provisions of Rule 419 promulgated under the Securities Act other than through its net tangible assets or (b) have at least $5,000,001 of net tangible assets either immediately prior to or upon consummation of the Business Combination, and (iii) extension of the outside date for the closing of the Business Combination from May 31, 2023, to February 7, 2024.                  
Conduit Pharmaceuticals Limited [Member] | Business Combination Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock issued value, acquisitions     $ 650,000,000              
Share issued price per share     $ 10.00              
Conduit Pharmaceuticals Limited [Member] | Subscription Agreements [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock issued value, acquisitions     $ 27,000,000              
IPO [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock issued during period shares new issues       13,225,000            
Proceeds from isssuance       $ 132,250,000            
Sale of stock             13,225,000      
Sale of stock price per share             $ 10.00      
Net proceeds from sale of equity       $ 139,790,000            
Share issued price per share             $ 10.00      
Private Placement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Sale of stock       754,000     754,000      
Sale of stock price per share       $ 10.00     $ 10.00      
Gross proceeds from shares issuance       $ 7,540,000            
Overfunding of trust account       4,895,000            
Operating cash account       2,000,000            
Offering costs       $ 2,895,000            
v3.23.2
SCHEDULE OF COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION (Details) - USD ($)
3 Months Ended 6 Months Ended
Jan. 26, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Accounting Policies [Abstract]              
Proceeds from Issuance Initial Public Offering         $ 132,250,000 $ 132,250,000
Proceeds allocated to Public Warrants         (23,276,000)    
Class A common stock issuance costs         (6,360,054)    
Remeasurement adjustment of carrying value to redemption value   $ 247,094 $ 158,900 $ 1,876,183 32,281,054    
Common stock subject to possible redemption, ending   22,861,803 136,771,183     136,771,183  
Remeasurement adjustment of carrying value to redemption value $ (114,000,000)   (114,068,280)        
Common stock subject to possible redemption, ending   $ 23,108,897 $ 22,861,803 $ 136,771,183 $ 134,895,000 $ 23,108,897  
v3.23.2
SCHEDULE OF BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Common Class A [Member]        
Allocation of net loss $ (161,829) $ (95,057) $ (126,879) $ (285,946)
Basic weighted average shares outstanding 2,941,728 13,979,000 4,344,254 11,105,539
Diluted weighted average shares outstanding 2,941,728 13,979,000 4,344,254 11,105,539
Basic net loss per common share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
Diluted net loss per common share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
Common Class B [Member]        
Allocation of net loss $ (181,882) $ (22,482) $ (96,563) $ (85,129)
Basic weighted average shares outstanding 3,306,250 3,306,250 3,306,250 3,306,250
Diluted weighted average shares outstanding 3,306,250 3,306,250 3,306,250 3,306,250
Basic net loss per common share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
Diluted net loss per common share $ (0.06) $ (0.01) $ (0.03) $ (0.03)
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jan. 26, 2023
Dec. 31, 2022
Cash $ 277,761     $ 345,777
Assets held-in-trust, noncurrent 23,339,887   $ 23,300,000 136,871,183
Offering costs 7,738,161      
Underwriting fees 2,645,000      
Deferred underwriting fee 4,628,750      
Initial public offering costs $ 464,411      
Stock redeemed, during period shares 11,037,272      
Temporary equity, carrying amount, attributable to parent $ 23,108,897     136,771,183
Accrued excise tax redemptions $ 1,140,683    
Class of warrant or right, outstanding 13,979,000      
Federal deposit insurance corporation premium expense $ 250,000      
Investments held in trust $ 23,300,000     $ 136,900,000
Common Class A [Member]        
Stock Issued During Period Shares Stock Options Exercised 11,037,272      
Stock Issued During Period Value Stock Options Exercised $ 114,068,280      
Exercise tax liability 1.00%      
Accrued excise tax redemptions $ 1,140,683      
Public Warrants [Member]        
Warrant issuance cost 1,358,457      
Private Placement Warrants [Member]        
Warrant issuance cost $ 19,656      
v3.23.2
INITIAL PUBLIC OFFERING (Details Narrative) - $ / shares
6 Months Ended
Jun. 30, 2023
Jan. 26, 2023
Nov. 16, 2021
Shares issued price per share   $ 0.035  
Common Class A [Member]      
Sale of stock price per share     $ 12.00
Shares issued price per share $ 10.33    
IPO [Member]      
Sale of stock 13,225,000    
Sale of stock price per share $ 10.00    
Shares issued price per share 10.00    
IPO [Member] | Common Class A [Member] | Public Warrant [Member]      
Shares issued price per share $ 11.50    
v3.23.2
PRIVATE PLACEMENTS (Details Narrative) - USD ($)
6 Months Ended
Feb. 07, 2022
Jun. 30, 2023
Jun. 30, 2022
Subsidiary, Sale of Stock [Line Items]      
Proceeds from issuance of private placement   $ 7,540,000
Exercise price of warrants   $ 0.01  
Director [Member]      
Subsidiary, Sale of Stock [Line Items]      
Number of units transferred to director   15,000  
Private Placement [Member]      
Subsidiary, Sale of Stock [Line Items]      
Number of shares issued for private sale 754,000 754,000  
Sale of stock price per share $ 10.00 $ 10.00  
Proceeds from issuance of private placement   $ 7,540,000  
Private Placement [Member] | Capital Unit, Class A [Member]      
Subsidiary, Sale of Stock [Line Items]      
Exercise price of warrants   $ 11.50  
v3.23.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Mar. 07, 2023
Feb. 10, 2022
Jan. 26, 2022
Nov. 16, 2021
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Nov. 04, 2021
Related Party Transaction [Line Items]                      
Number of shares issued to sponsor, value             $ 7,520,350        
Stock surrendered and forfeited during period shares               11,037,272      
Related party description       (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property. However, our sponsor has agreed to transfer, but has not yet transferred, 15,000 placement units to each of our director nominees.              
Outstanding balance on promissory note         $ 750,000     $ 750,000    
Monthly payment for office space               10,000      
Administration fee related party         $ 376,266 $ 249,420   $ 853,672 $ 493,138    
Conversion price         $ 10.00     $ 10.00      
Maximum [Member]                      
Related Party Transaction [Line Items]                      
Conversion amount               $ 1,500,000      
Related Party [Member]                      
Related Party Transaction [Line Items]                      
Administration fee related party         $ 30,000 $ 30,000   60,000 $ 50,000    
Unsecured Promissory Note [Member]                      
Related Party Transaction [Line Items]                      
Principal amount                     $ 300,000
Payment of promissory not   $ 177,057                  
Promissory Note [Member]                      
Related Party Transaction [Line Items]                      
Principal amount $ 1,500,000                    
Proceeds from note payable $ 300,000       450,000            
Outstanding balance on promissory note         $ 750,000     $ 750,000      
Common Class A [Member]                      
Related Party Transaction [Line Items]                      
Sale of stock price per share       $ 12.00              
Sponsor [Member]                      
Related Party Transaction [Line Items]                      
Stock surrendered and forfeited during period shares     1,006,250                
Stock issued during period on hold     3,306,250                
Sponsor [Member] | Common Class B [Member]                      
Related Party Transaction [Line Items]                      
Sale of private placement units, net of offering costs, shares       4,312,500              
Number of shares issued to sponsor, value       $ 25,000              
v3.23.2
COMMITMENTS AND CONTINGENCIES (Details Narrative)
6 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Loss Contingencies [Line Items]  
Option exercised date Feb. 07, 2022
Cash underwriting discount | $ / shares $ 0.20
Underwriting discount $ 2,645,000
Deferred fee per share | $ / shares $ 0.35
Deferred fee $ 4,628,750
Underwriter expenses $ 150,000
Over-Allotment Option [Member] | Maximum [Member]  
Loss Contingencies [Line Items]  
Stock issued during period shares new issues | shares 1,725,000
Underwriter [Member]  
Loss Contingencies [Line Items]  
Advance payment for underwriter expenses $ 50,000
v3.23.2
STOCKHOLDERS’ DEFICIT (Details Narrative)
3 Months Ended 6 Months Ended
Jan. 26, 2023
USD ($)
$ / shares
Mar. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Class of Stock [Line Items]        
Preferred stock, shares authorized     1,000,000 1,000,000
Preferred stock, par value | $ / shares     $ 0.0001 $ 0.0001
Preferred stock, shares issued     0 0
Preferred stock, shares outstanding     0 0
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares     2,187,728 13,225,000
Stock Redeemed or Called During Period, Shares     11,037,272  
Stock Redeemed or Called During Period, Value | $ $ 114,000,000 $ 114,068,280    
Shares Issued, Price Per Share | $ / shares $ 0.035      
Warrant exercise price | $ / shares     $ 0.01  
Warrant [Member]        
Class of Stock [Line Items]        
Share price per shares | $ / shares     $ 18.00  
Private Placement Warrants and Public Warrants [Member]        
Class of Stock [Line Items]        
Warrants outstanding, value | $     $ 23,276,000  
Private Placement Warrants and Public Warrants [Member] | Measurement Input, Expected Term [Member]        
Class of Stock [Line Items]        
Warrant expected term     5 years  
Private Placement Warrants and Public Warrants [Member] | Measurement Input, Price Volatility [Member]        
Class of Stock [Line Items]        
Warrant measurement inputs     22  
Private Placement Warrants and Public Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]        
Class of Stock [Line Items]        
Warrant measurement inputs     0  
Private Placement Warrants and Public Warrants [Member] | Measurement Input, Discount Rate [Member]        
Class of Stock [Line Items]        
Warrant measurement inputs     1.76  
Common Class A [Member]        
Class of Stock [Line Items]        
Common stock, shares authorized     100,000,000 100,000,000
Common stock, par value | $ / shares     $ 0.0001 $ 0.0001
Common Stock, Voting Rights     Holders of Class A common stock are entitled to one vote for each share  
Common stock, shares outstanding     754,000 754,000
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares     2,187,728 13,225,000
Stock Redeemed or Called During Period, Value | $     $ 114,068,280  
Shares Issued, Price Per Share | $ / shares     $ 10.33  
Common stock, shares issued     754,000 754,000
Common Class B [Member]        
Class of Stock [Line Items]        
Common stock, shares authorized     10,000,000 10,000,000
Common stock, par value | $ / shares     $ 0.0001 $ 0.0001
Common stock, shares outstanding     3,306,250 3,306,250
Common stock, shares issued     3,306,250 3,306,250
v3.23.2
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES (Details) - USD ($)
Jun. 30, 2023
Jan. 26, 2023
Dec. 31, 2022
Assets:      
Investments held in Trust Account $ 23,339,887 $ 23,300,000 $ 136,871,183
Fair Value, Inputs, Level 1 [Member]      
Assets:      
Investments held in Trust Account $ 23,339,887   $ 136,871,183
v3.23.2
TAXES (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Statutory tax rate     21.00%
Change in valuation allowance, rate 162.00% 964.00%  
v3.23.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
Aug. 07, 2023
Jul. 06, 2023
Subsequent Event [Member]    
Subsequent Event [Line Items]    
Deposit $ 78,393 $ 77,800

Murphy Canyon Acquisition (NASDAQ:MURFU)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Murphy Canyon Acquisition Charts.
Murphy Canyon Acquisition (NASDAQ:MURFU)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Murphy Canyon Acquisition Charts.